130 related articles for article (PubMed ID: 31366860)
1. Comparison of the in Vivo Activities of Garenoxacin and Levofloxacin in a Murine Model of Pneumonia by Mixed-Infection with Streptococcus pneumoniae and Parvimonas micra.
Kato H; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
Jpn J Infect Dis; 2019 Nov; 72(6):407-412. PubMed ID: 31366860
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.
Kato H; Yamagishi Y; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2019 Apr; 25(4):311-313. PubMed ID: 30287186
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model.
Hagihara M; Kato H; Shibata Y; Sakanashi D; Asai N; Suematsu H; Yamagishi Y; Mikamo H
Anaerobe; 2021 Jun; 69():102346. PubMed ID: 33600958
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of garenoxacin and levofloxacin for the prophylaxis of febrile neutropenia].
Hata A; Katakami N; Masuda Y; Takashima K; Takeshita J; Tanaka K; Kaji R; Fujita S; Ose T; Kitajima N
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1119-23. PubMed ID: 25248895
[TBL] [Abstract][Full Text] [Related]
5. Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia.
Yamasaki R; Kanda J; Akahoshi Y; Nakano H; Ugai T; Wada H; Kawamura K; Ishihara Y; Sakamoto K; Sato M; Ashizawa M; Machishima T; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kako S; Nishida J; Kanda Y
Int J Hematol; 2017 Jun; 105(6):835-840. PubMed ID: 28168415
[TBL] [Abstract][Full Text] [Related]
6. [In vitro activity of sitafloxacin against clinical isolates in 2012].
Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y
Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of sitafloxacin against clinical isolates in 2009].
Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
[TBL] [Abstract][Full Text] [Related]
8. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
[TBL] [Abstract][Full Text] [Related]
9. [Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
Jpn J Antibiot; 2010 Aug; 63(4):312-8. PubMed ID: 21298864
[TBL] [Abstract][Full Text] [Related]
10. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
11. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of garenoxacin against in vitro biofilm formed by nontypeable Haemophilus influenzae.
Takahata M; Sugiura Y; Shinmura Y; Fukuda Y; Nomura N
J Infect Chemother; 2013 Jun; 19(3):441-6. PubMed ID: 23089895
[TBL] [Abstract][Full Text] [Related]
14. [Antimicrobial activity of oral quinolones against clinical isolates of Bifidobacterium group and Clostridium difficile].
Kimura M; Yamagishi Y; Terada M; Ohki E; Tanaka K; Watanabe K; Mikamo H
Jpn J Antibiot; 2010 Apr; 63(2):171-7. PubMed ID: 20919497
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection.
Fukuda Y; Furuya Y; Nozaki Y; Takahata M; Nomura N; Mitsuyama J
Diagn Microbiol Infect Dis; 2014 Feb; 78(2):168-71. PubMed ID: 24321356
[TBL] [Abstract][Full Text] [Related]
16. Rapid bactericidal activity of sitafloxacin against Streptococcus pneumoniae.
Kanda H; Inoue K; Okumura R; Hoshino K
Jpn J Antibiot; 2013 Feb; 66(1):9-23. PubMed ID: 23777013
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibility of clinically-isolated bacteria strains to respiratory quinolones and evaluation of antimicrobial agent efficacy by Monte Carlo simulation].
Kosaka T; Yamada Y; Kimura T; Kodama M; Fujitomo Y; Masaki N; Toshiaki K; Keisuke S; Fujita N
Jpn J Antibiot; 2016 Feb; 69(1):27-40. PubMed ID: 27290828
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of garenoxacin against group G Streptococcus dysgalactiae subsp. equisimilis.
Takahata M; Sugiura Y; Shiokawa Y; Futakuchi N; Fukuda Y; Nomura N; Mitsuyama J
Int J Antimicrob Agents; 2011 Sep; 38(3):226-30. PubMed ID: 21726983
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)".
Mukae H; Kawanami T; Yatera K; Yanagihara K; Yamamoto Y; Kakeya H; Tokimatsu I; Kadota J; Kohno S
J Infect Chemother; 2014 Jul; 20(7):417-22. PubMed ID: 24787737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
